Shares of Capricor Therapeutics (CAPR) have gained 32.6% over the past four weeks to close the last trading session at $5.19, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$18.75 indicates a potential upside of 261.3%. The mean estimate comprises four short-term price targets with a standard deviation of $14.45. While the lowest estimate of$8 indicates a 54.1% increase from t ...